Global Silent Thyroiditis Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2023 to 2030

Description

List of Tables

Silent thyroiditis is an autoimmune reaction that affects the thyroid gland. Hyperthyroidism can occur first, followed by hypothyroidism. Lymphocytic thyroiditis, subacute lymphocytic thyroiditis, and painless thyroiditis are other terms used to describe silent thyroiditis. The first indications of silent thyroiditis are fatigue, increased appetite, palpitations, weight loss, muscular cramps, and mood changes caused by an overactive thyroid gland. Fatigue, constipation, dry skin, weight gain, and cold intolerance are later signs of silent thyroiditis that occur due to an underactive thyroid (hypothyroidism). Silent thyroiditis usually resolves on its own within a year. The acute phase lasts three months.

Market Dynamics

The growing cases of silent thyroiditis, rising incidence of thyroid disease, rising healthcare expenditure, development of treatment options, rising government funding, and rising initiatives by government and private organizations to spread disease awareness are the factors that will drive the silent thyroiditis market. In addition, a rise in the research and development activities and emerging markets will provide beneficial opportunities for the silent thyroiditis market. However, the high cost of treatment and the adverse effects associated with the medicine may stifle silent thyroiditis market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of silent thyroiditis. The growth and trends of silent thyroiditis industry provide a holistic approach to this study.

Market Segmentation

This section of the silent thyroiditis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

Beta-Blockers
Thyroid Hormone Replacement
Others

By Diagnosis

Thyroid Hormones T3 And T4
Tsh, Radioactive Iodine Uptake
C-Reactive Protein
Erythrocyte Sedimentation Rate
Others

By Dosage

Tablet
Injection
Others

By Route Of Administration

Oral
Intravenous
Others

By End-Users

Clinic
Hospital
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Silent Thyroiditis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the silent thyroiditis market include Pierre Fabre group, ANI Pharmaceuticals, Inc., Mylan N.V., Novartis AG, King Pharma, GlaxoSmithKline plc, Lupin, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lilly, AstraZeneca, Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Bayer AG, Merck Sharp & Dohme Corp. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR11216702

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . SILENT THYROIDITIS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Treatment
- 3.7.2 By Diagnosis
- 3.7.3 By Dosage
- 3.7.4 By Route of Administration
- 3.7.5 By End-Users
- 3.7.6 By Distribution Channel
- 3.7.7 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY TREATMENT

6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Beta-blockers Market by Regions
6.5 Thyroid Hormone Replacement Market by Regions
6.6 Others Market by Regions

7 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY DIAGNOSIS

7.1 Overview by Diagnosis
7.2 Historical and Forecast Data
7.3 Analysis by Diagnosis
7.4 Thyroid hormones T3 and T4 Market by Regions
7.5 TSH, Radioactive Iodine Uptake Market by Regions
7.6 C-reactive Protein Market by Regions
7.7 Erythrocyte Sedimentation Rate Market by Regions
7.8 Others Market by Regions

8 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY DOSAGE

8.1 Overview by Dosage
8.2 Historical and Forecast Data
8.3 Analysis by Dosage
8.4 Tablet Market by Regions
8.5 Injection Market by Regions
8.6 Others Market by Regions

9 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

9.1 Overview by Route of Administration
9.2 Historical and Forecast Data
9.3 Analysis by Route of Administration
9.4 Oral Market by Regions
9.5 Intravenous Market by Regions
9.6 Others Market by Regions

10 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY END-USERS

10.1 Overview by End-Users
10.2 Historical and Forecast Data
10.3 Analysis by End-Users
10.4 Clinic Market by Regions
10.5 Hospital Market by Regions
10.6 Others Market by Regions

11 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

11.1 Overview by Distribution Channel
11.2 Historical and Forecast Data
11.3 Analysis by Distribution Channel
11.4 Hospital Pharmacy Market by Regions
11.5 Retail Pharmacy Market by Regions
11.6 Online Pharmacy Market by Regions

12 . GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY GEOGRAPHY

12.1. Regional Outlook
12.2. Introduction
12.3. North America
- 12.3.1. Overview, Historic and Forecast Data
- 12.3.2. North America By Segment
- 12.3.3. North America By Country
- 12.3.4. United State
- 12.3.5. Canada
- 12.3.6. Mexico
12.4. Europe
- 12.4.1. Overview, Historic and Forecast Data
- 12.4.2. Europe by Segment
- 12.4.3. Europe by Country
- 12.4.4. United Kingdom
- 12.4.5. France
- 12.4.6. Germany
- 12.4.7. Italy
- 12.4.8. Russia
- 12.4.9. Rest Of Europe
12.5. Asia Pacific
- 12.5.1. Overview, Historic and Forecast Data
- 12.5.2. Asia Pacific by Segment
- 12.5.3. Asia Pacific by Country
- 12.5.4. China
- 12.5.5. India
- 12.5.6. Japan
- 12.5.7. South Korea
- 12.5.8. Australia
- 12.5.9. Rest Of Asia Pacific
12.6. Latin America
- 12.6.1. Overview, Historic and Forecast Data
- 12.6.2. Latin America by Segment
- 12.6.3. Latin America by Country
- 12.6.4. Brazil
- 12.6.5. Argentina
- 12.6.6. Peru
- 12.6.7. Chile
- 12.6.8. Rest of Latin America
12.7. Middle East & Africa
- 12.7.1. Overview, Historic and Forecast Data
- 12.7.2. Middle East & Africa by Segment
- 12.7.3. Middle East & Africa by Country
- 12.7.4. Saudi Arabia
- 12.7.5. UAE
- 12.7.6. Israel
- 12.7.7. South Africa
- 12.7.8. Rest Of Middle East And Africa

13 . COMPETITIVE LANDSCAPE OF THE SILENT THYROIDITIS COMPANIES

13.1. Silent Thyroiditis Market Competition
13.2. Partnership/Collaboration/Agreement
13.3. Merger And Acquisitions
13.4. New Product Launch
13.5. Other Developments

14 . COMPANY PROFILES OF SILENT THYROIDITIS INDUSTRY

14.1. Company Share Analysis
14.2. Market Concentration Rate
14.3. Pierre Fabre Group
- 14.3.1. Company Overview
- 14.3.2. Financials
- 14.3.3. Products
- 14.3.4. Recent Developments
14.4. ANI Pharmaceuticals, Inc.
- 14.4.1. Company Overview
- 14.4.2. Financials
- 14.4.3. Products
- 14.4.4. Recent Developments
14.5. Mylan N.V.
- 14.5.1. Company Overview
- 14.5.2. Financials
- 14.5.3. Products
- 14.5.4. Recent Developments
14.6. Novartis AG
- 14.6.1. Company Overview
- 14.6.2. Financials
- 14.6.3. Products
- 14.6.4. Recent Developments
14.7. King Pharma
- 14.7.1. Company Overview
- 14.7.2. Financials
- 14.7.3. Products
- 14.7.4. Recent Developments
14.8. GlaxoSmithKline plc
- 14.8.1. Company Overview
- 14.8.2. Financials
- 14.8.3. Products
- 14.8.4. Recent Developments
14.9. Lupin
- 14.9.1. Company Overview
- 14.9.2. Financials
- 14.9.3. Products
- 14.9.4. Recent Developments
14.10. Sun Pharmaceutical Industries Ltd.
- 14.10.1. Company Overview
- 14.10.2. Financials
- 14.10.3. Products
- 14.10.4. Recent Developments
14.11. Teva Pharmaceutical Industries Ltd.
- 14.11.1. Company Overview
- 14.11.2. Financials
- 14.11.3. Products
- 14.11.4. Recent Developments
14.12. Pfizer Inc.
- 14.12.1. Company Overview
- 14.12.2. Financials
- 14.12.3. Products
- 14.12.4. Recent Developments
14.13. Sanofi
- 14.13.1. Company Overview
- 14.13.2. Financials
- 14.13.3. Products
- 14.13.4. Recent Developments
14.14. Lilly
- 14.14.1. Company Overview
- 14.14.2. Financials
- 14.14.3. Products
- 14.14.4. Recent Developments
14.15. AstraZeneca
- 14.15.1. Company Overview
- 14.15.2. Financials
- 14.15.3. Products
- 14.15.4. Recent Developments
14.16. Johnson & Johnson Private Limited
- 14.16.1. Company Overview
- 14.16.2. Financials
- 14.16.3. Products
- 14.16.4. Recent Developments
14.17. Bristol-Myers Squibb Company
- 14.17.1. Company Overview
- 14.17.2. Financials
- 14.17.3. Products
- 14.17.4. Recent Developments
14.18. Bayer AG
- 14.18.1. Company Overview
- 14.18.2. Financials
- 14.18.3. Products
- 14.18.4. Recent Developments
14.19. Merck Sharp & Dohme Corp.
- 14.19.1. Company Overview
- 14.19.2. Financials
- 14.19.3. Products
- 14.19.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies